There is no single best treatment for diabetes. The right approach depends on whether you have Type 1 or Type 2, how long you’ve had it, whether you have heart or kidney complications, and how your blood sugar responds to initial therapy. That said, the landscape has shifted dramatically in recent years. Newer medications now do far more than lower blood sugar: they protect the heart, preserve kidney function, and in some cases help people lose significant weight. Here’s what the current evidence supports.
Type 2 Diabetes: First-Line Medication
For people who need medication primarily to lower blood sugar and don’t have heart disease, heart failure, or kidney disease, metformin remains the most commonly used starting treatment. It’s inexpensive, well-studied over decades, and effective at reducing blood sugar without causing weight gain. The 2025 American Diabetes Association Standards of Care still list it as the historical first-line option for straightforward cases.
But “straightforward” is becoming the exception. Most people with Type 2 diabetes carry additional risks, and guidelines now steer treatment choices based on those risks rather than blood sugar alone. If you already have cardiovascular disease, are at high risk for it, or have chronic kidney disease, your doctor should be considering newer drug classes that directly reduce those dangers, regardless of whether your blood sugar is well-controlled on metformin.
GLP-1 Medications and Why They’ve Changed the Game
GLP-1 receptor agonists (you may know brand names like Ozempic, Mounjaro, or Wegovy) work by mimicking a gut hormone that triggers insulin release after meals, slows digestion, and reduces appetite. They’ve become central to Type 2 treatment because their benefits extend well beyond blood sugar. In large clinical trials, GLP-1 medications reduced the risk of cardiovascular death by 13%, all-cause death by 12%, and stroke by 16%. They also lowered the risk of kidney disease progression by roughly 22 to 32% depending on the specific drug studied.
Weight loss is another major advantage. In real-world data from the Mayo Clinic, patients with Type 2 diabetes on tirzepatide (a dual-action medication targeting both GLP-1 and another gut hormone called GIP) lost an average of 14% of their body weight over 12 months. That level of weight loss can fundamentally change the trajectory of the disease. Current guidelines now prefer GLP-1 medications over insulin when there’s no sign of insulin deficiency, a notable shift from how diabetes was treated even five years ago.
SGLT2 Inhibitors for Heart and Kidney Protection
SGLT2 inhibitors (such as empagliflozin and dapagliflozin) work differently. They block the kidneys from reabsorbing sugar, so excess glucose leaves through urine. The blood sugar reduction is modest, but the organ protection is striking. These drugs reduced the risk of hospitalization for heart failure by 31%, kidney disease progression by 37%, and acute kidney injury by 23%. They also cut all-cause mortality by 14%.
The heart failure benefit is particularly strong. SGLT2 inhibitors reduce scarring in heart muscle tissue and shift the heart’s energy metabolism in ways that appear protective. For anyone with Type 2 diabetes and existing heart failure or declining kidney function, these medications are now considered essential, not optional add-ons. Many people with complex risk profiles end up on both an SGLT2 inhibitor and a GLP-1 medication, because their protective effects target different organs through different pathways.
When Insulin Is Still Necessary
Insulin isn’t outdated. It’s still the right choice when blood sugar is dangerously high at diagnosis (an A1C above 10% or blood sugar above 300 mg/dL) or when symptoms like excessive thirst, frequent urination, and unexplained weight loss suggest the body simply isn’t producing enough insulin. In those situations, waiting to try oral medications first can be harmful.
For people with Type 2 diabetes who eventually need insulin after other treatments stop working, guidelines recommend trying a GLP-1 medication before jumping to insulin whenever possible. GLP-1 drugs carry less risk of low blood sugar episodes and weight gain, two of insulin’s most common downsides.
Type 1 Diabetes: Automated Insulin Delivery
Type 1 diabetes requires insulin, full stop. The pancreas produces little to none. But how that insulin gets delivered has evolved enormously. Automated insulin delivery systems, sometimes called artificial pancreas systems, pair an insulin pump with a continuous glucose monitor and an algorithm that adjusts insulin doses in real time.
A systematic review of 46 trials covering over 4,100 people found that advanced hybrid closed-loop systems increased time spent in the healthy blood sugar range (70 to 180 mg/dL) by about 24 percentage points compared to a standard insulin pump. They also reduced time spent dangerously high (above 250 mg/dL) by roughly 15 percentage points. Perhaps most importantly, they achieved a clinically meaningful A1C reduction of 1.0 percentage point, which substantially lowers the risk of long-term complications.
The clinical target for most adults with Type 1 or Type 2 diabetes using a continuous glucose monitor is to spend more than 70% of the day in range (70 to 180 mg/dL), which translates to about 16 hours and 48 minutes. Automated systems make hitting that target far more realistic, especially overnight when manual adjustments aren’t possible.
Lifestyle Changes Are Treatment, Not Just Prevention
The Diabetes Prevention Program, one of the largest and most influential diabetes studies ever conducted, found that losing just 7% of body weight and walking briskly for 150 minutes per week reduced the risk of developing Type 2 diabetes by 58%. That’s a more powerful effect than the medication arm of the same study achieved.
For people who already have Type 2 diabetes, the same principles apply as active treatment. Weight loss improves insulin sensitivity, lowers blood sugar, reduces blood pressure, and can decrease the need for medication. In some cases, it leads to remission. The current consensus definition of remission is an A1C below 6.5% that lasts at least three months after stopping all diabetes medications. Remission is most achievable in the early years after diagnosis, before the insulin-producing cells in the pancreas have sustained too much damage. Significant weight loss, whether through dietary changes, structured programs, or medications like GLP-1 drugs, is the most reliable path to getting there.
Matching Treatment to Your Situation
The best treatment depends on your specific profile. Here’s a simplified framework:
- Type 2 with no major complications: Lifestyle changes plus metformin remains a solid starting point. A GLP-1 medication may be added or substituted if blood sugar targets aren’t met or weight loss is a priority.
- Type 2 with heart disease or high cardiovascular risk: A GLP-1 receptor agonist is strongly recommended for its proven reduction in heart attacks, strokes, and cardiovascular death.
- Type 2 with heart failure or kidney disease: An SGLT2 inhibitor should be part of the regimen, given its 31% reduction in heart failure hospitalizations and 37% reduction in kidney disease progression.
- Type 2 with obesity: Dual-action GLP-1/GIP medications like tirzepatide offer the largest weight loss effect alongside blood sugar control.
- Type 1 diabetes: Insulin is required. An automated insulin delivery system offers the best glycemic control currently available, significantly outperforming standard pump therapy or manual injections.
Diabetes treatment is no longer a one-size-fits-all prescription. The shift toward choosing medications based on what else they protect, not just how well they lower blood sugar, means the conversation with your care team should go beyond A1C numbers. Your heart, kidneys, and weight all factor into the decision now, and the options available are more effective than they’ve ever been.